Drug research

Telitacicept

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as RC18; RC18-L

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)NCT05306574	Vor Biopharma	Phase 3	Terminated	2025-01-06Actual
Chinese Adults With Kidney DiseaseNCT07522099	ADARx Pharmaceuticals, Inc.	Phase 2	Recruiting	2028-07-10Estimated
Phase 3 Study of Telitacicept in Active Primary Sjögren's DiseaseNCT07404865	Vor Biopharma	Phase 3	Recruiting	2028-12Estimated
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)NCT06456580	Vor Biopharma	Phase 3	Recruiting	2027-05Estimated

Vor BiopharmaTerminatedPrimary completion: 2025-01-06 · Actual

Trial details

ADARx Pharmaceuticals, Inc.RecruitingPrimary completion: 2028-07-10 · Estimated

Trial details

Vor BiopharmaRecruitingPrimary completion: 2028-12 · Estimated

Trial details

Vor BiopharmaRecruitingPrimary completion: 2027-05 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.